London · Delayed Price · Currency is GBP · Price in GBX Diaceutics Statistics
Total Valuation
Diaceutics has a market cap or net worth of GBP 163.83 million. The enterprise value is 157.82 million.
| Market Cap | 163.83M |
| Enterprise Value | 157.82M |
Important Dates
The last earnings date was Tuesday, September 22, 2026.
| Earnings Date | Sep 22, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Diaceutics has 84.89 million shares outstanding. The number of shares has increased by 0.18% in one year.
| Current Share Class | 84.89M |
| Shares Outstanding | 84.89M |
| Shares Change (YoY) | +0.18% |
| Shares Change (QoQ) | -1.21% |
| Owned by Insiders (%) | 23.15% |
| Owned by Institutions (%) | 45.50% |
| Float | 48.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 226.00 |
| PS Ratio | 3.96 |
| PB Ratio | 4.23 |
| P/TBV Ratio | 7.12 |
| P/FCF Ratio | 42.16 |
| P/OCF Ratio | 41.76 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 37.75, with an EV/FCF ratio of 40.61.
| EV / Earnings | n/a |
| EV / Sales | 3.82 |
| EV / EBITDA | 37.75 |
| EV / EBIT | n/a |
| EV / FCF | 40.61 |
Financial Position
The company has a current ratio of 2.55, with a Debt / Equity ratio of 0.05.
| Current Ratio | 2.55 |
| Quick Ratio | 2.33 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.50 |
| Debt / FCF | 0.54 |
| Interest Coverage | -14.44 |
Financial Efficiency
Return on equity (ROE) is -0.71% and return on invested capital (ROIC) is -2.43%.
| Return on Equity (ROE) | -0.71% |
| Return on Assets (ROA) | -1.03% |
| Return on Invested Capital (ROIC) | -2.43% |
| Return on Capital Employed (ROCE) | -1.95% |
| Weighted Average Cost of Capital (WACC) | 9.02% |
| Revenue Per Employee | 201,605 |
| Profits Per Employee | -1,322 |
| Employee Count | 205 |
| Asset Turnover | 0.86 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -382,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.63% in the last 52 weeks. The beta is 0.88, so Diaceutics's price volatility has been lower than the market average.
| Beta (5Y) | 0.88 |
| 52-Week Price Change | +20.63% |
| 50-Day Moving Average | 148.92 |
| 200-Day Moving Average | 151.59 |
| Relative Strength Index (RSI) | 87.34 |
| Average Volume (20 Days) | 209,615 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Diaceutics had revenue of GBP 41.33 million and -271,000 in losses. Loss per share was -0.00.
| Revenue | 41.33M |
| Gross Profit | 34.25M |
| Operating Income | -794,000 |
| Pretax Income | -653,000 |
| Net Income | -271,000 |
| EBITDA | 3.86M |
| EBIT | -794,000 |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 8.10 million in cash and 2.09 million in debt, with a net cash position of 6.01 million or 0.07 per share.
| Cash & Cash Equivalents | 8.10M |
| Total Debt | 2.09M |
| Net Cash | 6.01M |
| Net Cash Per Share | 0.07 |
| Equity (Book Value) | 38.75M |
| Book Value Per Share | 0.46 |
| Working Capital | 17.89M |
Cash Flow
In the last 12 months, operating cash flow was 3.92 million and capital expenditures -37,000, giving a free cash flow of 3.89 million.
| Operating Cash Flow | 3.92M |
| Capital Expenditures | -37,000 |
| Depreciation & Amortization | 4.65M |
| Net Borrowing | -371,000 |
| Free Cash Flow | 3.89M |
| FCF Per Share | 0.05 |
Margins
Gross margin is 82.88%, with operating and profit margins of -1.92% and -0.66%.
| Gross Margin | 82.88% |
| Operating Margin | -1.92% |
| Pretax Margin | -1.58% |
| Profit Margin | -0.66% |
| EBITDA Margin | 9.33% |
| EBIT Margin | -1.92% |
| FCF Margin | 9.40% |
Dividends & Yields
Diaceutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.18% |
| Shareholder Yield | -0.18% |
| Earnings Yield | -0.17% |
| FCF Yield | 2.37% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Diaceutics is 213.00, which is 10.36% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 213.00 |
| Price Target Difference | 10.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 20.40% |
| EPS Growth Forecast (3Y) | 122.83% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Diaceutics has an Altman Z-Score of 7.91 and a Piotroski F-Score of 3.
| Altman Z-Score | 7.91 |
| Piotroski F-Score | 3 |